ID: MRFR/Pharma/3367-HCR | 110 Pages | Author: Rahul Gotadki | June 2023
Intended Audience
Figure 1:- Diastematomyelia market share, by region (%)
Sources: WHO, annual reports, press release, white paper, and company presentation
Segmentation
The diastematomyelia market is segmented on the basis of types, host, therapy, and end users.
On the basis of type, the market is segmented into dual dural sac (type 1), and single sac (type 2).
On the basis of host, the market is segmented into children and adults.
On the basis of therapy, the market is segmented into diagnosis & therapy. The diagnosis is further segmented into imaging techniques, and prenatal ultrasound. Imaging techniques are further categorised into Plain X-ray, CT, MRI and others. The therapy is further segmented into surgical intervention, scoliosis surgery, decompression (surgery), and others.
On the basis of end users, the market is segmented into hospital, clinics, ambulatory centers, and others.
Regional Analysis
The Americas dominates the diastematomyelia market owing to large patient population. According to the Brain and Spinal Cord Injury Rehabilitation, in 2015, over 259,000 people in the U.S. were suffering from spinal cord injury. Increasing number of patients suffering from diastematomyelia and other spinal disease have driven the growth of the Americas diastematomyelia market. Additionally, high per capita income and increasing government support for research & development will fuelled the growth of the market. Diastematomyelia is considered as a rare diseases thus, government and other private companies are trying to create awareness among the people by conducting different seminars. Increasing awareness among people regarding the disease and well-developed technology will create opportunities for the development of the market.
Europe accounts for the second largest diastematomyelia market, which is followed by Asia Pacific. Availability of funds for research, huge geriatric population, and government support for research & development projected to drive the market in Europe. The U.K and Germany are the major contributors for the market.
Asia Pacific is the fastest growing region in the diastematomyelia market owing to the presence of huge patient pool, rapidly developing economies, and increasing demand for the better treatment options. Majority of the market is driven by India and China owing to huge patient population.
Whereas, the Middle East & Africa owns the least share of the diastematomyelia market due to the presence of poor economy, especially, in the Africa region. The market of this region is dominated by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. However, Africa region shows the fastest growth for the Diastematomyelia Market
Research Methodology
Sources: WHO, annual reports, press release, white paper, and company presentation
Key players in diastematomyelia market
The major key players in the diastematomyelia market: 3M (US), GlaxoSmithKline PLC (U.K), Pfizer Inc. (U.S.), Lineage Medical, Inc. (U.S.), Johnson & Johnson Services Inc. (U.S.), Bristol-Myers Squibb and Company (U.S.), B. Braun (Germany), Stryker Corporation (U.S.), Argon Medical Devices, Inc (the Netherlands), Cook Medical (U.S.)
The Diastematomyelia Market CAGR would be 3.20% during the forecast period.
The Diastematomyelia Market report includes end users like hospital, clinics, ambulatory centers, and others.
The Americas would dominate the Diastematomyelia Market.
The fastest-growing Diastematomyelia Market would be Asia Pacific.
The Diastematomyelia Market I Europe would gain leverage from the UK and Germany.
Key Questions Answered
Why Choose Market Research Future?